Histone Deacetylase Inhibitor Applications in Cancer Therapy

Histone deacetylases (HDACs) catalyse removal of acetyl groups from lysine residues within histone tails, driving chromatin condensation and transcriptional repression. Dysregulation of HDAC activity is frequently observed across a spectrum of malignancies, where aberrant epigenetic silencing of tumour suppressor genes and modulation of non-histone substrates promote oncogenic programmes. Histone deacetylase inhibitors (HDACi) restore acetylation marks, inducing cell-cycle arrest, apoptosis, differentiation and immunomodulatory effects. Clinically approved HDACi—such as vorinostat, romidepsin, belinostat and panobinostat—have demonstrated efficacy in various haematological malignancies, while selective inhibitors targeting individual isozymes are under investigation to mitigate off-target toxicities. However, challenges including intrinsic and acquired resistance, dose-limiting toxicities and limited activity in solid tumours have prompted the exploration of combination regimens, biomarker-driven patient selection and next-generation molecules with improved pharmacokinetic and selectivity profiles. Advances in understanding HDAC isoform biology and the tumour microenvironment are driving tailored strategies to harness epigenetic plasticity for clinical benefit.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Histone Deacetylase Inhibitor Applications in Cancer Therapy publication trend

The graph below shows the total number of articles in histone deacetylase inhibitor applications in cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Histone deacetylase (HDAC): Enzyme that removes acetyl groups from histone and non-histone proteins, promoting chromatin condensation and gene repression.

Histone deacetylase inhibitor (HDACi): Compound that inhibits HDAC activity, leading to increased acetylation, relaxed chromatin structure and altered gene expression.

Epigenetic regulation: Control of gene expression through reversible chemical modifications of DNA and histones without altering the underlying DNA sequence.

Pan-HDAC inhibitor: Agent that non selectively targets multiple HDAC isoforms, often with broader activity and increased off-target effects.

Selective HDAC inhibitor: Agent designed to inhibit a specific HDAC isoform, aiming to reduce toxicity and improve therapeutic window.

NEDD9: Scaffolding protein that modulates cell adhesion and migration, implicated in metastasis.

FAK (focal adhesion kinase): Tyrosine kinase that regulates cellular motility and survival signalling at focal adhesions.

References

1. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression. Signal Transduction and Targeted Therapy (2023).
2. Advances in targeting histone deacetylase for treatment of solid tumors. Journal of Hematology & Oncology (2024).
3. Histone Deacetylase Inhibitors as Anticancer Drugs. International Journal of Molecular Sciences (2017).